Wall Street analyst estimates for Kymera Therapeutics, Inc. (KYMR): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-03 | $-1.25 | ||
| 2026-08-05 | $-0.62 | $-0.71 | +13.0% |
| 2026-04-30 | $-0.71 | $-0.89 | +20.2% |
| 2026-02-26 | $-0.97 | $-0.78 | -23.8% |
| 2025-11-04 | $-0.90 | $-0.71 | -26.8% |
| 2025-08-11 | $-0.95 | $-0.83 | -14.5% |
| 2025-05-09 | $-0.82 | $-0.92 | +10.9% |
| 2025-02-27 | $-0.88 | $-0.76 | -15.8% |
Valuation Ratios
| Price / Book | 7.56 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | $2.9M | $34.0M | $72.8M | $46.8M | $78.6M | $47.1M | $39.2M |
| Cost of Revenue | $205000 | $825000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -$205000 | $2.1M | $34.0M | $72.8M | $46.8M | $78.6M | $47.1M | $39.2M |
| Research & Development | $17.7M | $37.2M | $62.1M | $137.0M | $164.2M | $189.1M | $240.2M | $316.6M |
| Selling, General & Admin | $3.8M | $8.0M | $18.2M | $36.3M | $43.8M | $55.0M | $63.5M | $68.2M |
| Operating Expenses | $21.5M | $45.1M | $80.3M | $173.4M | $208.1M | $244.1M | $308.7M | $388.6M |
| Operating Income | -$21.5M | -$42.2M | -$46.3M | -$100.5M | -$161.3M | -$165.5M | -$261.6M | -$349.4M |
| EBITDA | -$21.2M | -$40.4M | -$43.7M | -$97.6M | -$151.7M | -$143.2M | -$216.2M | -$303.1M |
| Interest Expense | $16000 | $46000 | $115000 | $175000 | $176000 | $196000 | $249000 | $249000 |
| Pre-tax Income | -$21.5M | -$41.2M | -$45.6M | -$100.2M | -$154.8M | -$147.0M | -$223.9M | -$311.6M |
| Income Tax | $43859 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$21.5M | -$41.3M | -$45.6M | -$100.2M | -$154.8M | -$147.0M | -$223.9M | -$311.4M |
| EPS | $-0.48 | $-0.93 | $-0.99 | $-2.09 | $-2.87 | $-2.52 | $-2.98 | $-3.69 |
| EPS (Diluted) | $-0.48 | $-0.93 | $-0.99 | $-2.09 | $-2.87 | $-2.52 | $-2.98 | $-3.69 |
| Shares Outstanding (Diluted) | $44.5M | $44.5M | $44.6M | $48.0M | $53.9M | $58.4M | $75.0M | $84.4M |
Price
| Price | $116.33 |
| Market Cap | $9.6B |
| Exchange | NASDAQ |
| Country | US |
Related companies: AAPG · ACAD · ACLX · AKRO · CRNX · IMVT · NAMS
Explore sector: Healthcare · Biotechnology
More sections of KYMR: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks